Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Penguin Solutions | Apple | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The FY2025 10-K (fiscal year ended August 29, 2025) documents design-in niches but no durable excess return. In favour: the Competition section says some large rivals 'tend to have limited customization and service capabilities and are generally focused on higher-volume memory, storage, or compute products that are manufactured to industry-standard specifications'. It says the company's 'close collaboration with customers, customer-specific designs, long-lifecycle solutions, superior products and proprietary supply chain services create significant customer loyalty that may provide an advantage when competing against large international companies'. Against: the same filing says many competitors have 'substantially greater financial, technical, marketing, distribution and other resources' and 'lower cost structures'. Sales are made 'primarily pursuant to customer purchase orders and are not based on long-term supply agreements', and 'customers are not obligated to purchase our products even if we achieve a design win'. Large customers 'have exerted' pressure for price concessions, and the ten largest were 66% of fiscal 2025 net sales. GAAP operating income was 0.6%, 1.6% and 4.2% of net sales in fiscal 2023, 2024 and 2025, and fiscal 2024 had a net loss from continuing operations of $41.8 million. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) adds that Advanced Computing nine-month sales fell 20.6%, reflecting 'both the ongoing Penguin Edge wind down and hyperscale hardware sales in 2025 that did not recur in 2026'. The filing's own advantage claim is hedged ('may provide an advantage'): design-in niches exist, but the 10-K shows no durable excess return. | narrow Argued, not assumed. The FY2025 10-K does evidence a real moat in margin: total gross margin percentage rose 44.1% (2023) to 46.2% (2024) to 46.9% (2025) in markets the same filing describes as characterised by 'aggressive price competition, downward pressure on gross margins.' But the filing bounds the claim itself: it concedes 'a minority market share in the global smartphone, personal computer, tablet and wearables markets,' it discloses no retention, active-device or installed-base figure anywhere (its only 'large installed bases of active devices' reference describes competitors), and it discloses that both of the highest-margin layers are already being cut down by force -- Apple is 'currently subject to a court order preventing it from imposing any commission or fee on certain purchases' on the U.S. App Store storefront, has had to open 'alternative methods of distribution for iOS and iPadOS apps, alternative payment processing' in the EU, and warns that a reversal on appeal in the Google search case could impose remedies 'prohibiting Google from offering the Company commercial terms for search distribution.' A moat that earns 46.9% gross margin but whose most profitable layer is being narrowed by two courts and a regulator is narrow, not wide. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The strongest candidate moat source in the 10-K is design-in and qualification, a switching-cost argument, and the filing limits it too far to count. The risk factors say 'Our products are often incorporated into customers' systems at the design stage', and many specialty products 'are specifically designed for our OEM customers' systems or products'. But qualification is 'both product-specific and platform-specific', so a design win covers one platform. The filing notes that customers 'sometimes require us to re-qualify our products' for new platforms, which 'can be time-consuming and cause reductions in our net sales', so each new platform reopens the socket. It also says 'customers are not obligated to purchase our products even if we achieve a design win', and warns that OEMs designing in 'standardized or commodity components' could reduce demand for its 'higher priced specialized or customized solutions'. Scale is ruled out because the filing says many competitors have lower cost structures. Patents are ruled out as a durable source. The company holds about 1,650 of them and calls intellectual property 'an important aspect of our business', but it says its patents 'do not cover all of our technologies' and that competitors 'may design around our patented technologies'. It also says some products are 'built around mature industry standards and have less patent protection', so 'we cannot prevent our competitors from reverse-engineering and duplicating those products'. | switching costs The 10-K locates the durable advantage in an integrated stack and its third-party ecosystem, not in patents: it names 'a strong third-party software and accessories ecosystem' among the principal competitive factors and states the Company 'designs and develops nearly the entire solution for its products, including the hardware, operating system, numerous software applications and related services,' while explicitly disclaiming IP as the source -- 'No single intellectual property right is solely responsible for protecting the Company's products and services' and the Company 'relies primarily on the innovative skills, technical competence and marketing abilities of its personnel.' The remedies now in force confirm the diagnosis negatively: the same filing describes being required to permit alternative distribution and alternative payment processing in the EU and being barred from charging commission on certain linked-out purchases in the U.S. -- remedies aimed squarely at lowering the cost of leaving Apple's rails, which is what a switching-cost moat is. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | at parity The 10-K claims no share figure or rank in any segment. It says 'Our businesses compete with numerous global and local companies'. Its HPC and AI business 'competes primarily with global manufacturers of HPC and AI products and services'. For fault-tolerant solutions it says 'we primarily compete with manufacturers of enterprise servers and industrial computers'. Its memory business competes 'against memory module providers and, to a lesser extent, large semiconductor manufacturers'. The risk factors warn that larger competitors 'may be able to respond better to new or emerging technologies, such as generative AI'. Against that, the company's stated edge is customization and service, where it says some large rivals 'tend to have limited customization and service capabilities'. Its leadership language is self-description without share figures: Cree LED 'has been a leader in LED lighting technology', Stratus Technologies is 'a global leader in simplified, protected and autonomous computing platforms and services', and the memory business is 'a primary supplier of longer-lifecycle solutions to OEM customers'. A specialist that claims no rank and faces many larger, lower-cost rivals, while neither leading nor clearly trailing in its niches, is parity. | fast follower Apple leads on integration and margin rather than on units, and the filing says so: it 'has a minority market share in the global smartphone, personal computer, tablet and wearables markets,' while competitors have 'broad product lines, low-priced products, large installed bases of active devices, and large customer bases.' On the AI axis that defines this graph, Apple is following rather than leading -- it now licenses a rival's frontier models to power Siri (see the Apple Intelligence / Siri row and its citation) while pushing its own advantage down into silicon. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak The FY2025 10-K describes price as set by customers and the market. It says its large customers 'are able to exert, have exerted and we expect will continue to exert, pressure on us to make concessions on price and on terms and conditions'. It says 'The markets for our Integrated Memory products have historically been characterized by declines in average selling prices', and that 'Competitive pressure has led in the past and may continue to lead to intensified price competition resulting in lower net sales and lower profit margins'. Gross margin held in a narrow band: 28.8% in fiscal 2023, 29.1% in fiscal 2024 and 28.8% in fiscal 2025. The filing attributes each move to mix, for example higher-margin Advanced Computing service revenue in 2024, not to pricing. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) reports gross margin of 27.8% versus 29.3% a year earlier (27.7% versus 28.9% for nine months), which it attributes to the Penguin Edge wind-down and sales mix. Third-quarter Integrated Memory sales rose 111.4% (75.6% for nine months) as 'accelerating AI-driven demand drove favorable pricing and increased volume', and the 10-Q says that business has 'gross margins which are lower than the Company average'. | strong The 10-K's own gross-margin table: total gross margin percentage 44.1% (2023) to 46.2% (2024) to 46.9% (2025), with Services at 75.4% versus Products at 36.8%, and iPhone net sales rising 'due to higher net sales of Pro models' -- mix moving up, not down. Held against the filing's own hedge that 'gross margins will be subject to volatility and downward pressure,' the realised trend is the stronger evidence. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Penguin Solutions (formerly SMART Global Holdings) has three reportable segments per the FY2025 10-K. Advanced Computing ($648.4 million of fiscal 2025 net sales) designs, builds, deploys and manages AI and HPC clusters under OriginAI with the ICE ClusterWare software, and sells Stratus fault-tolerant servers. Integrated Memory ($464.2 million) sells SMART Modular specialty DRAM, flash and CXL memory and supply-chain services. Optimized LED ($256.1 million) sells Cree LED chips and components. Its advantage is customization rather than size. The filing says its memory business collaborates with OEMs 'throughout their design process across multiple projects' and is 'a primary supplier of longer-lifecycle solutions to OEM customers' in industrial, government, networking and enterprise markets. Its products must pass product- and platform-specific qualification, and some large rivals focus on higher-volume, industry-standard products. The limits are just as clear. Many competitors are larger and have lower cost structures. Customers buy on purchase orders, the ten largest were 66% of fiscal 2025 sales, and they 'have exerted' pressure for price concessions. Integrated Memory has historically seen declining average selling prices. AI hardware revenue is project-driven: Advanced Computing sales fell 26.0% in fiscal 2024 on 'the unpredictable nature of large project engagements'. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) says the AI infrastructure business is 'transitioning from a hyperscaler concentration toward a more diversified non-hyperscaler customer base across enterprise, neocloud, and sovereign AI', which 'may negatively impact our net sales during the transition'. The result is a set of design-in niches rather than a franchise, with an AI business that must keep re-winning large deployments. | Apple's moat is usually asserted through the ecosystem; the FY2025 10-K neither quantifies nor claims retention, so the evidence has to be read elsewhere in the filing. Where it does show is mix and margin: Services reached $109.2B of $416.2B net sales (+14%) at a 75.4% gross margin against 36.8% on Products, so 26% of revenue delivered $82.3B of the $195.2B total gross margin, and iPhone grew 'due to higher net sales of Pro models.' That profit concentration is also the vulnerability the filing itself flags: Apple 'earns revenue from licensing arrangements with Google LLC and other companies to offer their search services on the Company's platforms,' arrangements 'currently subject to government investigations and legal proceedings' after Google was found to have violated U.S. antitrust laws on August 5, 2024 and the D.C. District Court ordered remedies on September 2, 2025 -- with the 10-K warning that a reversal on appeal could impose DOJ's proposed remedies 'prohibiting Google from offering the Company commercial terms for search distribution,' which 'could materially adversely affect the Company's ability to earn revenue from such licensing arrangements.' Apple never discloses the size of that payment in the filing -- the concentration is admitted but not measured. Alongside it, the App Store toll has already been reduced in both jurisdictions. What is not in dispute is the vertical integration: Apple designs the silicon and now the cellular modem, and uses 'custom components available from only one source.' Read together: a genuine, margin-visible switching-cost moat around an integrated stack, with its two most profitable layers under active legal reduction. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Downstream integrator. Per the 10-K it buys memory from Samsung, Micron, SK hynix and Kioxia and processors from Intel and AMD, and turns them into specialty memory modules and managed AI/HPC clusters for OEM, enterprise, government and cloud customers. | Applications-layer name in the AI chain: the 10-K describes designing 'nearly the entire solution' and using custom components 'available from only one source,' making Apple a large, concentrated buyer of leading-edge silicon rather than a supplier of AI compute to anyone else. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.11 at weight 0.20 · swarm bullish Editorial prior, not backtested. |